drugset / Trial / NCT05940298
Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8
Phase 1
Completed
10 enrolled
Tomsk National Research Medical Center of the Russian Academy of Sciences
Uppsala University · collab
Non-randomizedParallel-groupSingle-blindDiagnostic
Summary
The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of \[99mTc\]Tc- DB8 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc- DB8. 3. To study the safety and tolerability of the drug \[99mTc\]Tc- DB8 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[99mTc\]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.
Timeline
- Start
- 2023-07-03
- Primary completion
- 2024-06-01
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [99mTc]Tc-DB8 | Unknown | — | Intravenous |